MARKET

LJPC

LJPC

La Jolla Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.360
-0.600
-12.10%
After Hours: 4.360 0 0.00% 17:51 03/27 EDT
OPEN
4.850
PREV CLOSE
4.960
HIGH
4.850
LOW
4.330
VOLUME
588.86K
TURNOVER
--
52 WEEK HIGH
13.90
52 WEEK LOW
2.300
MARKET CAP
118.66M
P/E (TTM)
-1.0144
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LJPC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LJPC stock price target is 13.75 with a high estimate of 20.00 and a low estimate of 4.000.

EPS

LJPC News

More
  • The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals
  • Benzinga · 03/13 14:53
  • OXY, NRZ among premarket gainers
  • Seeking Alpha - Article · 03/13 13:25
  • La Jolla Pharmaceutical Company to Provide GIAPREZA (Angiotensin II) in Italy for Compassionate Use in Patients with Septic Shock Associated with COVID-19
  • GlobeNewswire · 03/13 13:00
  • La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) in Italy for Compassionate Use in Patients with Septic Shock Associated with COVID-19
  • Benzinga · 03/13 12:13

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About LJPC

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
More

Webull offers kinds of La Jolla Pharmaceutical Company stock information, including NASDAQ:LJPC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LJPC stock news, and many more online research tools to help you make informed decisions.